Inhibition of acetyl-CoA carboxylases by soraphen A prevents lipid accumulation and adipocyte differentiation in 3T3-L1 cells

Elizabeth L. Cordonier, Sarah K. Jarecke, Frances E. Hollinger, Janos Zempleni

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Acetyl-CoA carboxylases (ACC) 1 and 2 catalyze the carboxylation of acetyl-CoA to malonyl-CoA and depend on biotin as a coenzyme. ACC1 localizes in the cytoplasm and produces malonyl-CoA for fatty acid (FA) synthesis. ACC2 localizes in the outer mitochondrial membrane and produces malonyl-CoA that inhibits FA import into mitochondria for subsequent oxidation. We hypothesized that ACCs are checkpoints in adipocyte differentiation and tested this hypothesis using the ACC1 and ACC2 inhibitor soraphen A (SA) in murine 3T3-L1 preadipocytes. When 3T3-L1 cells were treated with 100 nM SA for 8 days after induction of differentiation, the expression of PPARγ mRNA and FABP4 mRNA decreased by 40% and 50%, respectively, compared with solvent controls; the decrease in gene expression was accompanied by a decrease in FABP4 protein expression and associated with a decrease in lipid droplet accumulation. The rate of FA oxidation was 300% greater in SA-treated cells compared with vehicle controls. Treatment with exogenous palmitate restored PPARγ and FABP4 mRNA expression and FABP4 protein expression in SA-treated cells. In contrast, SA did not alter lipid accumulation if treatment was initiated on day eight after induction of differentiation. We conclude that loss of ACC1-dependent FA synthesis and loss of ACC2-dependent inhibition of FA oxidation prevent lipid accumulation in adipocytes and inhibit early stages of adipocyte differentiation.

Original languageEnglish (US)
Pages (from-to)202-208
Number of pages7
JournalEuropean Journal of Pharmacology
Volume780
DOIs
StatePublished - Jun 5 2016

Fingerprint

3T3-L1 Cells
Acetyl-CoA Carboxylase
Adipocytes
Malonyl Coenzyme A
Fatty Acids
Lipids
Peroxisome Proliferator-Activated Receptors
Messenger RNA
Acetyl Coenzyme A
Palmitates
Coenzymes
Mitochondrial Membranes
Biotin
Mitochondria
Cytoplasm
Proteins
soraphen A
Gene Expression

Keywords

  • Acetyl-CoA carboxylase
  • Adipogenesis
  • Lipid metabolism
  • Peroxisome-proliferator-activated receptor gamma
  • Soraphen A

ASJC Scopus subject areas

  • Pharmacology

Cite this

Inhibition of acetyl-CoA carboxylases by soraphen A prevents lipid accumulation and adipocyte differentiation in 3T3-L1 cells. / Cordonier, Elizabeth L.; Jarecke, Sarah K.; Hollinger, Frances E.; Zempleni, Janos.

In: European Journal of Pharmacology, Vol. 780, 05.06.2016, p. 202-208.

Research output: Contribution to journalArticle

@article{dde2c1c9d20049be862e7805ce3ab4d8,
title = "Inhibition of acetyl-CoA carboxylases by soraphen A prevents lipid accumulation and adipocyte differentiation in 3T3-L1 cells",
abstract = "Acetyl-CoA carboxylases (ACC) 1 and 2 catalyze the carboxylation of acetyl-CoA to malonyl-CoA and depend on biotin as a coenzyme. ACC1 localizes in the cytoplasm and produces malonyl-CoA for fatty acid (FA) synthesis. ACC2 localizes in the outer mitochondrial membrane and produces malonyl-CoA that inhibits FA import into mitochondria for subsequent oxidation. We hypothesized that ACCs are checkpoints in adipocyte differentiation and tested this hypothesis using the ACC1 and ACC2 inhibitor soraphen A (SA) in murine 3T3-L1 preadipocytes. When 3T3-L1 cells were treated with 100 nM SA for 8 days after induction of differentiation, the expression of PPARγ mRNA and FABP4 mRNA decreased by 40{\%} and 50{\%}, respectively, compared with solvent controls; the decrease in gene expression was accompanied by a decrease in FABP4 protein expression and associated with a decrease in lipid droplet accumulation. The rate of FA oxidation was 300{\%} greater in SA-treated cells compared with vehicle controls. Treatment with exogenous palmitate restored PPARγ and FABP4 mRNA expression and FABP4 protein expression in SA-treated cells. In contrast, SA did not alter lipid accumulation if treatment was initiated on day eight after induction of differentiation. We conclude that loss of ACC1-dependent FA synthesis and loss of ACC2-dependent inhibition of FA oxidation prevent lipid accumulation in adipocytes and inhibit early stages of adipocyte differentiation.",
keywords = "Acetyl-CoA carboxylase, Adipogenesis, Lipid metabolism, Peroxisome-proliferator-activated receptor gamma, Soraphen A",
author = "Cordonier, {Elizabeth L.} and Jarecke, {Sarah K.} and Hollinger, {Frances E.} and Janos Zempleni",
year = "2016",
month = "6",
day = "5",
doi = "10.1016/j.ejphar.2016.03.052",
language = "English (US)",
volume = "780",
pages = "202--208",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Inhibition of acetyl-CoA carboxylases by soraphen A prevents lipid accumulation and adipocyte differentiation in 3T3-L1 cells

AU - Cordonier, Elizabeth L.

AU - Jarecke, Sarah K.

AU - Hollinger, Frances E.

AU - Zempleni, Janos

PY - 2016/6/5

Y1 - 2016/6/5

N2 - Acetyl-CoA carboxylases (ACC) 1 and 2 catalyze the carboxylation of acetyl-CoA to malonyl-CoA and depend on biotin as a coenzyme. ACC1 localizes in the cytoplasm and produces malonyl-CoA for fatty acid (FA) synthesis. ACC2 localizes in the outer mitochondrial membrane and produces malonyl-CoA that inhibits FA import into mitochondria for subsequent oxidation. We hypothesized that ACCs are checkpoints in adipocyte differentiation and tested this hypothesis using the ACC1 and ACC2 inhibitor soraphen A (SA) in murine 3T3-L1 preadipocytes. When 3T3-L1 cells were treated with 100 nM SA for 8 days after induction of differentiation, the expression of PPARγ mRNA and FABP4 mRNA decreased by 40% and 50%, respectively, compared with solvent controls; the decrease in gene expression was accompanied by a decrease in FABP4 protein expression and associated with a decrease in lipid droplet accumulation. The rate of FA oxidation was 300% greater in SA-treated cells compared with vehicle controls. Treatment with exogenous palmitate restored PPARγ and FABP4 mRNA expression and FABP4 protein expression in SA-treated cells. In contrast, SA did not alter lipid accumulation if treatment was initiated on day eight after induction of differentiation. We conclude that loss of ACC1-dependent FA synthesis and loss of ACC2-dependent inhibition of FA oxidation prevent lipid accumulation in adipocytes and inhibit early stages of adipocyte differentiation.

AB - Acetyl-CoA carboxylases (ACC) 1 and 2 catalyze the carboxylation of acetyl-CoA to malonyl-CoA and depend on biotin as a coenzyme. ACC1 localizes in the cytoplasm and produces malonyl-CoA for fatty acid (FA) synthesis. ACC2 localizes in the outer mitochondrial membrane and produces malonyl-CoA that inhibits FA import into mitochondria for subsequent oxidation. We hypothesized that ACCs are checkpoints in adipocyte differentiation and tested this hypothesis using the ACC1 and ACC2 inhibitor soraphen A (SA) in murine 3T3-L1 preadipocytes. When 3T3-L1 cells were treated with 100 nM SA for 8 days after induction of differentiation, the expression of PPARγ mRNA and FABP4 mRNA decreased by 40% and 50%, respectively, compared with solvent controls; the decrease in gene expression was accompanied by a decrease in FABP4 protein expression and associated with a decrease in lipid droplet accumulation. The rate of FA oxidation was 300% greater in SA-treated cells compared with vehicle controls. Treatment with exogenous palmitate restored PPARγ and FABP4 mRNA expression and FABP4 protein expression in SA-treated cells. In contrast, SA did not alter lipid accumulation if treatment was initiated on day eight after induction of differentiation. We conclude that loss of ACC1-dependent FA synthesis and loss of ACC2-dependent inhibition of FA oxidation prevent lipid accumulation in adipocytes and inhibit early stages of adipocyte differentiation.

KW - Acetyl-CoA carboxylase

KW - Adipogenesis

KW - Lipid metabolism

KW - Peroxisome-proliferator-activated receptor gamma

KW - Soraphen A

UR - http://www.scopus.com/inward/record.url?scp=84964329791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964329791&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2016.03.052

DO - 10.1016/j.ejphar.2016.03.052

M3 - Article

C2 - 27041646

AN - SCOPUS:84964329791

VL - 780

SP - 202

EP - 208

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -